Senior Vice President of Commercial Operations
Theresa Schaub is the Senior Vice President of Commercial Operations for DiscoverX. Ms. Schaub joined DiscoverX in 2015 and brings over 15 years of commercialization experience within the life sciences and biotechnology industry. Ms. Schaub was previously with Affymetrix Corp. from 2010-2015, where she was Vice President of Marketing. She led corporate strategy, product commercialization, and integrated multi-channel global marketing for the company. Ms. Schaub has experience in leading growth in small, complex business units, in rebranding and growing mature businesses, and in the integration of acquisition assets and brands. In her role as Senior Vice President of Commercial Operations, Ms. Schaub is responsible for all aspects of commercial strategy, global marketing, corporate brand, marketing communications, and new product development launch and lifecycle.
Ms. Schaub has a B.A. degree in Chemistry from Chapman University and an MBA from University of Redlands in Global Business and Marketing.
Senior Vice President of Sales and Distribution
David Martz has been with DiscoverX since 2011 and currently serves as Senior Vice President of Sales and Distribution where he is responsible for the management of direct sales teams in North America and Europe and distributors across the Asia-Pacific region. Mr. Martz brings over 20 years of sales and marketing experience in the life sciences industry, and has had success growing revenue at both large and small companies, primarily focusing on technological leadership and the development of new markets. Previously, he was with QIAGEN, after it acquired SABiosciences, where he was Senior Vice President of Sales and Marketing for 5 years. During his career he has worked for several global companies, including Roche Diagnostics, Incyte Genomics, Clontech and Amersham, in a variety of sales and management roles.
Mr. Martz received his B.S. degree in Molecular Biology and B.A. degree in Economics from the University of Washington and an MBA from the University of Maryland.
Senior Vice President and General Manager of Services Division
Justin Mika is the Senior Vice President and General Manger of the Global Services Division. Mr. Mika has 15 years of experience in the life sciences and drug discovery industries and began his career at Princeton University studying the role of genes and ferrous metals in regulating key cellular processes. He joined Thomas Scientific in 2013 and had increasing roles in the commercial organization. Mr. Mika joined DiscoverX in 2006 and has held senior leadership roles in North American Sales, Business Development, Marketing, and Drug Discovery Operations.
Mr. Mika received his B.S. degree from Pennsylvania State University and M.S. and MBA from the University of Delaware.
Senior Vice President and General Manager of Products Division
Sailaja Kuchibhatla serves as Senior Vice President and General Manager of the Global Products Division. Ms. Kuchibhatla has over 25 years of experience in the life sciences and drug discovery industries and began her career at Clontech in 1989 within the R&D organization. After several years of varied and increasing responsibility within R&D, she moved into Marketing, followed by her appointment as VP of Business Development, where she was a key member of the marketing, business development and new technology licensing group. She was also a member of the Senior Leadership Team at BD Biosciences/Clontech and a member of the Technology Strategy and Business Development team at BD Biosciences. Ms. Kuchibhatla joined DiscoverX in 2004 and has held senior leadership roles in Marketing, Asia Pacific Sales, Corporate Development, Legal and IP management.
Ms. Kuchibhatla holds a M.S. in Plant Sciences.
Christopher W. Clarke
Vice President of IT Strategy
Chris Clarke currently serves as Vice President of IT Strategy for DiscoverX and leads the global IT function. Prior to DiscoverX, Mr. Clarke was Chief Information Officer for Tonbo Biosciences where he led ecommerce and commercial operations. As Director of E-Business and Information Technology at Becton Dickinson and Co. for seven years, Mr. Clarke led the development and launch of BD’s first ecommerce platform in 2005. For the past ten years, he has held various roles in DevOps leadership for early-stage startups. An early adopter of Linux and network-based computing platforms, Mr. Clarke has a strong technical background in information management, cloud computing, and systems integration in life sciences.
Mr. Clarke received his M.S. in Biology from Virginia Commonwealth University and a B.S. degree in Biology and Environmental Science from Davis and Elkins College.
Ellen L. Berg, Ph.D.
Chief Scientific Officer, BioSeek Division
Dr. Ellen L. Berg is Chief Scientific Officer for the DiscoverX BioSeek Business Unit. Dr. Berg is responsible for the BioMAP® platform of human primary cell-based assays and predictive analysis tools. Dr. Berg was a founder and the CSO of BioSeek, acquired by DiscoverX in 2012, and previously led a research team at Protein Design Labs developing novel therapeutic antibodies for inflammatory diseases. She is an expert in in vitro models of human disease and tissue biology, holds a number of patents, and has authored over 75 publications in the areas of inflammation, systems biology, phenotypic drug discovery, and drug and toxicity mechanisms of action. Dr. Berg has served in various positions with the Society of Laboratory Automation and Screening and is a member of the Society of Toxicology.
Dr. Berg has a Ph.D. from Northwestern University and was a Postdoctoral Fellow at Stanford University.
Daniel K. Treiber, Ph.D.
Chief Scientific Officer, Drug Discovery Services
Dr. Daniel K. Treiber is Chief Scientific Officer for Drug Discovery Services. Dr. Treiber co-invented and developed the KINOMEscan® and BROMOscan® screening platforms and InCELL Pulse™ cellular target engagement assay technology. Dr. Treiber has broad expertise in the areas of biochemical and cellular assay technology development and small molecule kinase inhibitor drug discovery and pre-clinical development. Dr. Treiber was previously at Ambit Biosciences where he held leadership positions on multiple kinase-focused drug discovery teams and contributed to the strategic design of quizartinib, a FLT3 kinase inhibitor currently in Phase III studies for the treatment of acute myelogenous leukemia. Dr. Treiber holds several patents and has authored 25 peer-reviewed publications.
Dr. Treiber has a Ph.D. from MIT and was a Postdoctoral Fellow at The Scripps Research Institute.